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Background: A pharmacoinvasive strategy may alleviate the logistical and geographical
barriers in timely reperfusion of ST-segment elevation myocardial infarction (STEMI),
especially in a developing country like India.
Aim: To assess the safety and efﬁcacy of pharmacoinvasive strategy versus primary PCI in
STEMI patients at 2 years.
Methods: Patients enrolled in STEPP-AMI, an observational, multicenter, prospective study
of 200 patients presenting with STEMI, were followed up for 2 years. Group 'A' comprised of
patients with pharmacoinvasive strategy (n = 45), and patients who underwent primary PCI
(n = 155) formed group 'B'. Primary endpoint was composite of death, cardiogenic shock,
reinfarction, repeat revascularization of the culprit artery, or congestive heart failure at 30
days, with follow-up till 2 years.
Results: The primary endpoint occurred in 11.1% and 17.8% in group A and in 3.9% and 13.6%
in group B, at 30 days and 2 years, respectively ( p = 0.07, RR = 2.87; 95% CI: 0.92–8.97 at 30 days
and p = 0.47, RR = 1.31; 95% CI: 0.62–2.76). There was no difference in bleeding risk between
groups, 2.2% in group A and 0.6% in group B ('p' = 0.4). The infarct-related artery patency
varied at angiogram; it was 82.2% in arm A and 22.6% in arm B ('p' < 0.001). In group A, failed
ﬁbrinolysis occurred in 12.1%.
§ The study was conducted by Madras Medical Mission, Chennai, India.
§§ Trial is registered with Clinical trial registry of India, CTRI number: REF/2011/07/002556.
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Conclusion: A pharmacoinvasive strategy resulted in outcomes that were comparable with
primary PCI at 2 years, suggesting it might be a viable option in India. Larger studies are
required to conﬁrm these ﬁndings.
# 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 1 6 9 – 1 7 31701. Introduction
ST-segment elevation myocardial infarction (STEMI) is a life
threatening manifestation of coronary artery disease (CAD)
requiring timely reperfusion. The incidence of STEMI is higher
in the Indian population when compared to developed
countries and results in signiﬁcant mortality.1 The current
recommendations maintain primary percutaneous coronary
intervention (PCI) as the treatment of choice in the manage-
ment of STEMI, contingent upon rapid initiation of treatment
at centers with a skilled PCI laboratory within suggested
timelines.2 However, unavailability of primary PCI capable
hospitals across India and delays in transport have restricted
the access to this life-saving modality to less than 10% of
patients with STEMI.3 Of those, patients who do reach the
hospital early still have to deal with other issues, such as
arranging for ﬁnances, as most Indian patients pay out-of
pocket, even for the emergency services, such as primary PCI.4
On the other hand, introduction of ﬁbrin-speciﬁc lytic
agents like tenecteplase (TNK) has improved the infarct-
related artery (IRA) patency rates signiﬁcantly.5 Rapid ﬁbrino-
lytic treatment after STEMI improved the outcomes in patients
treated within an hour of symptom onset, with tapering
beneﬁts after 3 h.6 However, ﬁbrinolysis is associated with
high rates of reocclusion of IRA, hence a strategy of initial
bolus lysis followed by early coronary angiogram within 3–24 h
of ﬁbrinolysis, with an appropriate PCI, now known as
'pharmacoinvasive strategy,'7 has been considered as a good
alternative in the treatment of STEMI, especially in a
developing country such as India.8
2. Methods
This is prospective, observational, multicenter pilot study,
which was conducted between August 2011 and May 2013.
Study sites, which were capable of performing 24/7 primary
PCI, were selected from Tamilnadu (3), Karnataka (1), and
Kerala (1). All study centers were well equipped to handle
cardiac emergencies. A total of 200 patients who fulﬁlled the
inclusion/exclusion criteria with STEMI were enrolled in the
study. Written informed consent was signed by all the patients
and the study has been cleared by the ethics committees of the
respective hospitals. As this is an observational study, the
treatment options were chosen entirely by the patient and the
attendants; hence, some patients who presented outside the
recommended timelines for thrombolysis have received lytic
therapy although all centers in the study were equipped with
24  7 primary PCI facilities. Thrombolysis was performed in
the ICU of the hospital in all centers.The aim of the study is to assess the safety, efﬁcacy, and
feasibility of a pharmacoinvasive strategy in comparison to
primary PCI in patients with STEMI. The trial's inclusion and
exclusion criteria and study protocol are described in the
primary publication.9 Deﬁnitions used in the study are given in
the appendix.
3. Endpoints
Our primary endpoint was set at 30 days and is a composite of
death, cardiogenic shock, reinfarction, repeat revasculariza-
tion, and congestive heart failure, and extended to 2 years.
Safety endpoints are bleeding endpoints assessed using the
TIMI classiﬁcation at 30 days.
4. Statistical analysis
The detailed description of statistical analysis is published
previously.9 As this was a pilot study, primarily conducted to
assess feasibility of a pharmacoinvasive strategy in STEMI
patients, a sample size of 200 patients was deemed sufﬁcient
for the study. Statistical analyses were performed using SAS
software, version 9.2. Chi-square or Mantel-Haenszel test or
Fischer's exact test were used for observed differences
between groups. Relative risk estimates with 95% conﬁdence
intervals and Kaplan–Meier curves were used to compare
differences in outcomes. A p-value of 0.05 was considered
signiﬁcant for all the statistical evaluations.
5. Results
The results of this trial, up to 1-year follow-up, have been
published previously.9 Out of the 200 total patients enrolled, the
pharmacoinvasive arm (arm 'A') had 45 patients and PPCI arm
(arm 'B') had 155 patients. Baseline characteristics were no
different between both groups, except more patients in arm B
were in killip's class I.9 The salient points of procedural
characteristics of patients are that 6.7% (n = 3) patients in arm
A had insigniﬁcant disease; hence no intervention was
performed for them, whereas 100% of patients in arm B required
angioplasty and stent implantation. Patients in arm A also had
better TIMI ﬂow at CAG (TIMI 3 ﬂow in 27.9%), higher radial
procedures (76.7%), more IRA patency (82.2%), and less
thrombus burden.9 In arm 'A', 12.1% was the incidence of failed
thrombolysis.
The timelines for the study are given in Table 1; median total
ischemic times are similar for both groups (245 min vs. 260 min);
average door-to-balloon time is 80 min and the door-to-needle
Table 2 – Safety endpoints.
A B 'p' value
Bleeding
Any bleeding – n (%) 1 (2.2) 4 (2.6) 1.0
Intracranial bleeding – n 0 0 NA
Bleeding at access site – n (%) 1 (2.2) 0 0.22
TMI Bleeding
Major – n (%) 0 1 (0.6) 1.0
Requiring medical attention – n (%) 0 1 (0.6) 1.0
Minimal – n (%) 1 (2.2) 2 (1.3) 0.54
Reproduced with permission from ‘‘Open Heart-BMJ’’
NA – not applicable.
Table 1 – Important timelines for the study.
Parameter 'A' 'B' 'p' value
Total ischemic time (minutes) 0.69
Median 245 260
Interquartile range 185–395 185–390
Door-to-balloon time (minutes) NA
Median 0 80
Interquartile range 0 60–120
Door-to-needle time (minutes) NA
Median 47 0
Interquartile range 35–75 0
Reproduced with permission from ‘‘Open Heart-BMJ’’
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published earlier9 and the safety endpoints are given in Table 29;
there is no difference in bleeding outcomes between both
groups (2.2% vs. 2.6%, 'p' not signiﬁcant). The efﬁcacy endpoints
are studied at 30 days, 3 months, 6 months, 1 year, and 2 years;
there is no difference between both groups in efﬁcacy endpoints
at any time period although there is trend of beneﬁt for arm B inTable 3 – Efficacy endpoints.
Endpoints A (n = 45)
n (%)
B (n = 155)
n (%)
Death, reinfarction, repeat revascularization of culprit artery, cardiogeni
At 30 days 5 (11.1) 6 (3.9) 
At 3 months 6 (13.3) 9 (5.8) 
At 6 months 6 (13.3) 11 (7.1) 
At 1 year 6 (13.3) 14 (9.0) 
At 2 year 8 (17.8) 21 (13.6) 
Efﬁcacy endpoint – death
At 30 days 3 (6.7) 2 (1.3) 
At 3 months 4 (8.9) 4 (2.6) 
At 6 months 4 (8.9) 5 (3.2) 
At 1 year 4 (8.9) 7 (4.5) 
At 2 years 5 (11.1) 13 (8.4) 
Efﬁcacy endpoint – death/reinfarction
At 30 days 3 (6.7) 5 (3.2) 
At 3 months 4 (8.9) 7 (4.5) 
At 6 months 4 (8.9) 8 (5.2) 
At 1 year 4 (8.9) 10 (6.4) 
At 2 years 5 (11.1) 16 (10.3) 
CHF – congestive heart failure.the initial few months (Table 3). The efﬁcacy endpoints were
adjusted for age, sex, and killips's class at presentation and were
found to be no different between both groups (Table 4). The
Kaplan–Meier curves for the primary endpoints are shown in
Fig. 1. At the end of 2 years, 2 patients were lost to follow-up in
arm 'A'.
6. Discussion
In this study, we have evaluated the strategy of pharmacoin-
vasive management of STEMI versus primary PCI. The primary
endpoint was set at 30 days consisting of death, cardiogenic
shock, reinfarction, repeat revascularization, and congestive
heart failure, which was similar in both groups, although there
was a trend toward beneﬁt in the primary PCI group (11.1% vs.
3.9%, p = 0.07, RR = 2.87; 95% CI: 0.92–8.97).9 At the end of 2-year
follow-up, the initial beneﬁt from primary PCI seems to be
narrowed as more events have occurred in the primary PCI
group (A-17.8% vs. B-13.6%, p = 0.47, RR = 1.31; 95% CI: 0.62–
2.76). The additions of events in the primary endpoint of
primary PCI group are mainly due to death and repeat
revascularization. This may be partly due to the fact that
6.7% of patients in the pharmacoinvasive group did not require
a stent placement due to insigniﬁcant disease at the angio-
gram, which means they are at no risk of stent thrombosis or
restenosis. The non-urgent basis on which the angioplasty
was performed in the pharmacoinvasive group may also have
inﬂuenced the primary endpoint over a period of time, but this
fact needs further large studies to provide comprehensive
evidence.
The STREAM trial is one of the pivotal trials, which
compared the pharmacoinvasive strategy with primary PCI
in STEMI patients.10 The combined primary endpoint of death,
shock, congestive heart failure, or re-infarction was similar'p' value Relative risk
Estimate 95% CI
c shock, CHF
0.07 2.87 0.92–8.97
0.10 2.30 0.86–6.11
0.19 1.88 0.74–4.80
0.40 1.48 0.60–3.62
0.47 1.31 0.62–2.76
0.07 5.17 0.89–29.98
0.07 3.44 0.90–13.23
0.12 2.76 0.77– 9.83
0.26 1.97 0.60–6.42
0.57 1.32 0.50–3.52
0.31 2.07 0.51–8.32
0.26 1.97 0.60–6.42
0.36 1.72 0.54–5.46
0.57 1.38 0.45–4.18
0.88 1.08 0.42–2.78
Table 4 – Efficacy endpoints (after adjusting for age, sex, and killip's class as covariates).
Endpoints A (n = 45)
n (%)
B (n = 155)
n (%)
'p' value Relative risk
Estimate 95% CI
Death, reinfarction, repeat revascularization, cardiogenic shock, CHF
At 30 days 5 (11.1) 6 (3.9) 0.12 2.22 0.81–6.13
At 3 months 6 (13.3) 9 (5.8) 0.23 1.70 0.72–4.05
At 6 months 6 (13.3) 11 (7.1) 0.34 1.50 0.65–3.43
At 1 year 6 (13.3) 14 (9.0) 0.64 1.21 0.54–2.71
At 2 years 8 (17.8) 21 (13.6) 0.69 1.15 0.57–2.33
CHF – congestive heart failure.
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The FAST-MI Registry evaluated the ‘‘real world’’ management
of 1492 patients with STEMI in France, who sought medical
treatment within 12 h of symptom onset.12
Ninety-six percent of the patients treated with ﬁbrinolysis
underwent coronary angiography within 3–24 h and 84%
underwent subsequent PCI. Survival at 5 years was 88% in
the ﬁbrinolysis group and 84% for those in PPCI group.
(HR = 0.73; CI: 0.50–1.06; p = 0.1). However, pre-hospital ﬁbrino-
lysis resulted in lower 5-year mortality (HR = 0.57; CI: 0.36–
0.88), whereas in-hospital ﬁbrinolysis was associated with a
tendency toward increased 5-year mortality (HR = 1.19; CI:
0.72–1.96) when compared to primary PCI.
Gershlick et al. performed a pre-speciﬁed analysis of
STREAM cohort according to PCI-related delay.13 Data from
hospitals that enrolled more than 10 randomized patientsFig. 1 – Kaplan–Meier curves for the primary endpoint. The prim
reinfarction, repeat revascularization, and congestive heart failu
intervention.were used in the analysis and PCI-related delay was catego-
rized as ≤55, >55–97, and >97 min. While there was no
worsening outcomes of death/congestive heart failure/cardio-
genic shock/myocardial infarction for pharmacoinvasive
patients across the PCI-related delay, as this delay increased
to >55 min, patients in pharmacoinvasive strategy had better
outcomes than primary PCI strategy, suggesting an event-
free advantage with pharmacoinvasive strategy (p
(interaction) = 0.094). Further analysis of PCI-related delay
demonstrated that for every 10 min increase of this delay,
there was a rising trend of beneﬁt among pharmacoinvasive
strategy patients (p(interaction) = 0.073).
Because of the small and uneven sample size between the
groups of the study, our ﬁndings may not provide an exact
estimate of outcomes and larger randomized trials are
required to conﬁrm these ﬁndings. Further discussion of theary endpoint was a composite of death, cardiogenic shock,
re at 2 years (p = 0.40). PCI, percutaneous coronary
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primary publication.9
7. Conclusion
Current guidelines sustain primary PCI to be the reperfusion
strategy of choice in patients with STEMI contingent upon
treatment at centers with a skilled PCI laboratory and rapid
initiation. However, increasingly more data support a phar-
macoinvasive strategy as an efﬁcient therapeutic option in
patients with STEMI. Our study showed that ﬁbrinolysis
followed by an early coronary angiogram within 3–24 h with
PCI, if appropriate, resulted in similar outcomes when
compared to primary PCI in patients with STEMI at 2-year
follow-up. These ﬁndings lend further support to the adoption
of a pharmacoinvasive strategy where patient and system-
related delays are inherent.
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